Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,871 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Discovery of preventive drugs for cisplatin-induced acute kidney injury using big data analysis.
Kanda M, Goda M, Maegawa A, Yoshioka T, Yoshida A, Miyata K, Aizawa F, Niimura T, Hamano H, Okada N, Sakurada T, Chuma M, Yagi K, Izawa-Ishizawa Y, Yanagawa H, Zamami Y, Ishizawa K. Kanda M, et al. Among authors: miyata k. Clin Transl Sci. 2022 Jul;15(7):1664-1675. doi: 10.1111/cts.13282. Epub 2022 Apr 30. Clin Transl Sci. 2022. PMID: 35445533 Free PMC article.
Identification of prophylactic drugs for oxaliplatin-induced peripheral neuropathy using big data.
Zamami Y, Niimura T, Kawashiri T, Goda M, Naito Y, Fukushima K, Ushio S, Aizawa F, Hamano H, Okada N, Yagi K, Miyata K, Takechi K, Chuma M, Koyama T, Kobayashi D, Shimazoe T, Fujino H, Izawa-Ishizawa Y, Ishizawa K. Zamami Y, et al. Among authors: miyata k. Biomed Pharmacother. 2022 Apr;148:112744. doi: 10.1016/j.biopha.2022.112744. Epub 2022 Feb 28. Biomed Pharmacother. 2022. PMID: 35240525 Free article.
Association Between Statin Use and Daptomycin-related Musculoskeletal Adverse Events: A Mixed Approach Combining a Meta-analysis and a Disproportionality Analysis.
Chuma M, Nakamoto A, Bando T, Niimura T, Kondo Y, Hamano H, Okada N, Asada M, Zamami Y, Takechi K, Goda M, Miyata K, Yagi K, Yoshioka T, Izawa-Ishizawa Y, Yanagawa H, Tasaki Y, Ishizawa K. Chuma M, et al. Among authors: miyata k. Clin Infect Dis. 2022 Oct 12;75(8):1416-1422. doi: 10.1093/cid/ciac128. Clin Infect Dis. 2022. PMID: 35262686 Free PMC article.
Investigation of drugs for the prevention of doxorubicin-induced cardiac events using big data analysis.
Nishiuchi S, Yagi K, Saito H, Zamami Y, Niimura T, Miyata K, Sakamoto Y, Fukunaga K, Ishida S, Hamano H, Aizawa F, Goda M, Chuma M, Izawa-Ishizawa Y, Nawa H, Yanagawa H, Kanda Y, Ishizawa K. Nishiuchi S, et al. Among authors: miyata k. Eur J Pharmacol. 2022 Aug 5;928:175083. doi: 10.1016/j.ejphar.2022.175083. Epub 2022 May 31. Eur J Pharmacol. 2022. PMID: 35659512 Free article.
Non-recovery of vancomycin-associated nephrotoxicity is related to worsening survival outcomes: Combined retrospective analyses of two real-world databases.
Chuma M, Hamano H, Bando T, Kondo M, Okada N, Izumi Y, Ishida S, Yoshioka T, Asada M, Niimura T, Zamami Y, Takechi K, Goda M, Miyata K, Yagi K, Kasamo S, Izawa-Ishizawa Y, Azuma M, Yanagawa H, Tasaki Y, Ishizawa K. Chuma M, et al. Among authors: miyata k. Basic Clin Pharmacol Toxicol. 2022 Dec;131(6):525-535. doi: 10.1111/bcpt.13799. Epub 2022 Oct 7. Basic Clin Pharmacol Toxicol. 2022. PMID: 36169161 Free article.
Characterization of Immune Checkpoint Inhibitor-Induced Myasthenia Gravis Using the US Food and Drug Administration Adverse Event Reporting System.
Niimura T, Zamami Y, Miyata K, Mikami T, Asada M, Fukushima K, Yoshino M, Mitsuboshi S, Okada N, Hamano H, Sakurada T, Matsuoka-Ando R, Aizawa F, Yagi K, Goda M, Chuma M, Koyama T, Izawa-Ishizawa Y, Yanagawa H, Fujino H, Yamanishi Y, Ishizawa K. Niimura T, et al. Among authors: miyata k. J Clin Pharmacol. 2023 Apr;63(4):473-479. doi: 10.1002/jcph.2187. Epub 2022 Dec 21. J Clin Pharmacol. 2023. PMID: 36453166
Differential effects of proton pump inhibitors and vonoprazan on vascular endothelial growth factor expression in cancer cells.
Ando-Matsuoka R, Yagi K, Takaoka M, Sakajiri Y, Shibata T, Sawada R, Maruo A, Miyata K, Aizawa F, Hamano H, Niimura T, Izawa-Ishizawa Y, Goda M, Sakaguchi S, Zamami Y, Yamanishi Y, Ishizawa K. Ando-Matsuoka R, et al. Among authors: miyata k. Drug Dev Res. 2023 Feb;84(1):75-83. doi: 10.1002/ddr.22013. Epub 2022 Dec 9. Drug Dev Res. 2023. PMID: 36484282
Cardiovascular Toxicities Associated with Anaplastic Lymphoma Kinase Inhibitors: A Disproportionality Analysis of the WHO Pharmacovigilance Database (VigiBase).
Niimura T, Miyata K, Hamano H, Nounin Y, Unten H, Yoshino M, Mitsuboshi S, Aizawa F, Yagi K, Koyama T, Goda M, Kanda Y, Izawa-Ishizawa Y, Zamami Y, Ishizawa K. Niimura T, et al. Among authors: miyata k. Drug Saf. 2023 Jun;46(6):545-552. doi: 10.1007/s40264-023-01300-9. Epub 2023 Apr 27. Drug Saf. 2023. PMID: 37106270
1,871 results